FDA Approves Outlook Therapeutics' LYTENAVA as First Ophthalmic Bevacizumab for Wet AMD After Three Prior CRLs
Three complete response letters. One successful appeal. One approval.
Editorial Read →
Small-cap biotech intelligence
The catalysts moving small-cap biotech — every trading day.
Daily commentary on FDA decisions, trial readouts, financings and the stocks reacting to them — plus live market, filings and news trackers.
The Briefing
Charts by TradingView
Live Trackers
Full market view →Market Pulse
Sector heat & sentiment
silvergoldcopperlithiumcobaltnickel
Spot gold (+1.24% to ~$4,424 USD/oz) and silver (+1.06% to ~$65.36 USD/oz) extended their multi-month rallies on August 12, sustaining a broadly bulli…
News Wire
Latest headlines
- Nine Mile Metals Announces Certified Assays of 3.49% Cu-Eq over 24.55 meters (True Width) in DDH WD-26-09
- Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
- Errington Metals Announces Closing of C$34.5 Million Private Placement
- Alaska Silver Announces C$7.6 Million Pipe Financing to Expand 2026 Drill Program to 9,000 Metres
Filings Watch
Recent filings
- Scotia Metals Corp. — RTO / Reverse Merger, August 4, 2026
- Critical Elements Lithium Corporation — Exploration Update, August 4, 2026
- Canadian Copper Inc. — Material Change Report, August 4, 2026
Latest Articles
All articles →InduPro Closes $77M Series B, Doses First Patient in IDP-001 Phase 1 — Merck, Sanofi, and Lilly All At the Table
InduPro, Inc. closed a $77 million Series B financing and dosed the first patient in its Phase 1 study of IDP-001 on August 12, 2026, per a Business Wire release that day. The Seattle-based private…
Editorial Read →
Capricor's August 22 PDUFA Date Arrives With the Stock Up 97.39% on August 14 and a 3–9 Advisory Vote Hanging Over It
The most consequential binary event in small-cap biotech this week lands on Friday, August 22: the FDA's PDUFA decision on Capricor Therapeutics' (CAPR) deramiocel BLA for Duchenne muscular dystrophy…
Editorial Read →
Ultragenyx's DTX401 Faces August 23 PDUFA Date With No Approved Competition in GSD-Ia
Ultragenyx Pharmaceutical (NASDAQ: RARE) has a hard regulatory date on the calendar: the FDA's August 23, 2026 PDUFA decision on DTX401 (pariglasgene brecaparvovec), an AAV8 gene therapy for Glycogen…
Editorial Read →
Quantum BioPharma Wins FDA Clearance for Phase 2 Lucid-MS Trial, Holds US$9.5M Cash With Runway to at Least October 2027
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) received FDA clearance on August 14, 2026 to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis, per the…
Editorial Read →
Replimune's Tudriqev Wins FDA Accelerated Approval After Two Rejections — 24.2% ORR, $450K List Price, $140.5M Raise Closes
Replimune Group (NASDAQ: REPL) cleared its hardest regulatory hurdle on August 6, 2026: FDA accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults…
Editorial Read →
Corbus Pharmaceuticals Gets FDA Green Light for TEMPO-1 Registrational Study in Oropharyngeal Cancer, Backed by $138M Cash Position
Corbus Pharmaceuticals (NASDAQ: CRBP) received FDA clearance on July 28, 2026 to initiate TEMPO-1, a registrational study of CRB-701 in second-line oropharyngeal squamous cell carcinoma (OPSCC) — a…
Editorial Read →
Attovia Therapeutics Prices $289M Upsized IPO, Opens 29% Above Offer on Nasdaq Debut
Attovia Therapeutics priced its initial public offering on August 4, 2026, and began trading on the Nasdaq Global Market on August 5, 2026 under the symbol "ATTO" — closing its first session at…
Editorial Read →
Capricor's Deramiocel Faces 9-3 AdCom Rejection With FDA Decision Due August 22
The FDA's advisory committee delivered a lopsided verdict on Capricor Therapeutics' Deramiocel on July 29, 2026: 9 against, 3 for, 0 abstaining on whether available evidence supported the therapy's…
Editorial Read →
13 Biotech IPOs Have Already Raised $5.0 Billion in 2026 — Topping Every Full-Year Total Since 2021
Thirteen biotech offerings have priced through late June, raising $5.0 billion in aggregate — a figure that already exceeds every full-year total from 2022 through 2025, according to data reported at…
Editorial Read →
Attovia Therapeutics Raises $289M in Upsized IPO, Opens 23.5% Above Offer Price on Nasdaq Debut
Attovia Therapeutics, Inc. (Nasdaq: ATTO) priced its initial public offering at $17.00 per share on August 4, 2026 — the top of its targeted range — raising $289.0 million in gross proceeds before…
Editorial Read →
Zhengye Biotechnology Clears Nasdaq Minimum Bid Requirement, ZYBT Surges 133.59% on August 6
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) regained compliance with Nasdaq's minimum bid price rule on August 5, 2026 — and the stock responded with a violent move the following session.
Editorial Read →
Never miss a catalyst.
One concise briefing. The movers, the filings, the FDA calendar.